author-photo

Reece Caldwell

Institute of Cancer Research

5

Papers

30

Citations

Citation Trend

Filter By

Papers (5) Sort By

JournalConferenceOthers

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

2021 Elements
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (23)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号